Screener
Vertex Pharmaceuticals VRTX Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderOtherAmount.
The source filing: Vertex Pharmaceuticals’s 10-K, filed February 13, 2026.
- Filed
- Feb 13, 2026, 4:20 PM EST
- Fiscal year
- FY2025
- Accession
- 0000875320-26-000056
| Line item | Amount | Percentage |
|---|---|---|
| Deferred charges related to intra-entity transfers | (61.5) | (1.3)% |
| Foreign-derived deduction eligible income | (58.5) | (1.3)% |
| Subpart F income, net of credits | (97.4) | (2.1)% |
| Other | 0.8 | —% |
| Tax credits | ||
| Research and development tax credits | (154.4) | (3.3)% |
| Nontaxable or nondeductible items | ||
| Stock compensation (benefit), shortfalls and cancellations | (61.9) | (1.3)% |
ITEM 16.FORM 10-K SUMMARY
FAQ
- What is Vertex Pharmaceuticals's other operating expenses?
- Vertex Pharmaceuticals (VRTX) reported other operating expenses of $200K in Q4 2025.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Vertex Pharmaceuticals's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude